Preemstvennost' provedeniya dvoynoy antitrombotsitarnoy terapii u bol'nykh, perenesshikh ostryy koronarnyy sindrom: vse li voprosy resheny?

Cover Page
  • Authors: Lopatin Y.M1,2
  • Affiliations:
    1. ФГБОУ ВПО Волгоградский государственный медицинский университет Минздрава России
    2. ГБУЗ Волгоградский областной клинический кардиологический центр
  • Issue: Vol 16, No 1 (2014)
  • Pages: 47-51
  • Section: Articles
  • URL: https://journals.rcsi.science/2075-1753/article/view/94035
  • ID: 94035

Cite item

Full Text

Abstract

В контексте вопроса о преемственности проведения двойной антитромбоцитарной терапии ДАТТ у больных, перенесших острый коронарный синдром ОКС, представляется важным выделение особенностей госпитального и амбулаторного этапов оказания помощи данной категории пациентов. При всей очевидности и схожести главных целей лечения больных с ОКС на госпитальном и амбулаторном этапах, если говорить о снижении риска смерти и улучшении прогноза, для каждого этапа характерны свои особенности, которые необходимо учитывать при проведении ДАТТ. Улучшение преемственности в проведении ДАТТ на госпитальном и амбулаторном этапах рассматривается как важный фактор повышения приверженности лечению больных с ОКС. Решение этой задачи носит комплексный характер, объединяющий усилия как органов здравоохранения, так и медицинских работников и пациентов, и в конечном итоге обеспечивает снижение риска развития неблагоприятных сердечно-сосудистых исходов у данной категории больных.

About the authors

Yu. M Lopatin

ФГБОУ ВПО Волгоградский государственный медицинский университет Минздрава России; ГБУЗ Волгоградский областной клинический кардиологический центр

References

  1. Hamm C.W, Bassand J.P, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
  2. Steg Ph. G, James S.K, Atar D et al. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.
  3. ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 2013; 127: e663-e828; doi: 10.1161/CIR.0b013e31828478ac
  4. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association. Task Force on Practice Guidelines. Circulation 2013; 127: 1-89; doi: 10.1161/CIR.0b013e3182742cf6
  5. Yusuf S, Zhao F, Mehta S.R et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
  6. Mehta S.R, Yusuf S, Peters R.J et al. Effects of pretreatment with clopidogrel and aspirin followed by long - term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
  7. Mehta S.R, Tanguay J-F, Eikelboom J.W et al. Double - dose versus standard - dose clopidogrel and high - dose versus low - dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-43.
  8. Patti G, Bárczi G, Orlic D et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty - Myocardial Infarction) randomized study. J Am Coll Cardiol 2011; 58: 1592-9.
  9. Mauri L, Kereiakes D.J, Normand S.L et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug - eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010; 160: 1035-41.
  10. Helft G, Le Feuvre C, Georges J-L et al. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug - eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials 2013; 14: 56-72.
  11. Ho P.M, Peterson E.D, Wang L et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299: 532-9.
  12. Collet J.P, Montalescot G, Blanchet B et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361-7.
  13. Эрлих А.Д. от имени всех участников регистров РЕКОРД и РЕКОРД-2. Изменения частоты использования двойной антитромбоцитарной терапии у больных с острым коронарным синдромом. Клин. фармакология и терапия. 2012; 21 (4): 1-5.
  14. Melloni C, Alexander K.P, Ou F.S. Predictors of early discontinuation of evidence - based medicine after acute coronary syndrome. Am J Cardiol 2009; 104: 175-81.
  15. Spertus J.A, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug - eluting stent placement: results from the PREMIER registry. Circulation 2006; 113 (24): 2803-9.
  16. Kherada N, Sartori S, Vadde R et al. Predictors of Dual Antiplatelet Therapy Non-Adherence after PCI: One-Year Insights from the PARIS Registry. JACC 2013; 61 (10): E1597.
  17. Baber U, Colombo A, Weisz G et al. Association of Stent Thrombosis and Patterns of Non - adherence to Anti - platelet Regimens in Stented Patients: Six Month Results of the PARIS Registry JACC 2012; 59: E269.
  18. Faxon D, Brown M. Antiplatelet therapy for postdischarge medical management of acute coronary syndrome. Am J Med 2008; 121: 171-8.
  19. Bagnall A.J, Yan A.T, Yan R.T et al. Canadian Acute Coronary Syndromes Registry II Investigators. Optimal medical therapy for non-ST-segment - elevation acute coronary syndromes: exploring why physicians do not prescribe evidence - based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010; 3: 530-7.
  20. Rinfret S, Rodés-Cabau J, Bagur R et al. For the EASY-IMPACT Investigators Telephone contact to improve adherence to dual antiplatelet therapy after drug - eluting stent implantation. Heart 2013; doi: 10.1136/heartjnl-2012-303004
  21. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm and Biomed Analysis 2004; 34: 341-8.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies